The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Increased glucose metabolism and uptake are characteristic of many tumors and used
clinically to diagnose and monitor cancer progression. In addition to cancer cells, the tumor …

CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

The metabolic state represents a major hurdle for an effective adoptive T cell therapy (ACT).
Indeed, specific lipids can harm CD8+ T cell (CTL) mitochondrial integrity, leading to …

Cancer is now considered a tumor microenvironment (TME) disease, although it was
originally thought to be a cell and gene expression disorder. Over the past 20 years …

The metabolically hostile tumour microenvironment imposes barriers to tumour-infiltrating
immune cells and impedes durable clinical remission following immunotherapy. Metabolic …

Expansion of antigen-experienced CD8+ T cells is critical for the success of tumour-
infiltrating lymphocyte (TIL)-adoptive cell therapy (ACT) in patients with cancer. Interleukin-2 …

T cell responses must be balanced to ensure adequate protection against malignant
transformation and an array of pathogens while also limiting damage to healthy cells and …

Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …